SunWay 2020 annual revenue was 314 million and will be listed on Taiwan Emerging Stock Market on January 18, 2021.


On January 12, SunWay Biotech Co., LTD. (1271) was invited by Fubon Securities Co., Ltd. to participate in the institutional investor conference. John Pan, President of SunWay Biotech, introduced two main ingredients-ANKASCIN 568-R and Vigiis 101-LAB probiotics and their application, and announced that SunWay Biotech will be listed on Taiwan Emerging Stock Market on January 18, 2021.